A Clinical Update on Hypothalamic-Pituitary Control

  • M. D. Page
  • J. Webster
  • C. Dieguez
  • R. Hall
  • M. F. Scanlon
Conference paper
Part of the Acta Neurochirurgica book series (NEUROCHIRURGICA, volume 47)


Over the last three decades major advances in the understanding of hypothalamic-pituitary control mechanisms have led to important diagnostic and therapeutic developments. The early work of Geoffrey Harris, which established the concept of hypothalamic-pituitary control via the microvascular portal system was confirmed by the isolation by Guillemin and Schally in the late 1960’s and early 1970’s, of a variety of chemical mediators of these actions, the hypothalamic regulatory peptides. In more recent times the two most elusive hypothalamic regulatory peptides, corticotrophin releasing factor and growth hormone releasing factor (Table 1) have been isolated and characterised through the efforts of Vale and Guillemin. In this brief review we outline some of the more recent developments which have led to improvements in clinical management of the various endocrine conditions associated with disturbances of specific anterior pituitary hormones.


Pituitary Adenoma Thyroid Stimulate Hormone Growth Hormone Response Growth Hormone Release Anterior Pituitary Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Atiea JA, Creagh F, Page MD, Owens DR, Scanlon MF, Peters JR (1989) Early morning hyperglycaemia in IDD. Acute effects of cholinergic blockade. Diabetes (in press)Google Scholar
  2. Atiea JA, Creagh F, Page MD, Owens DR, Scanlon MF, Peters JR (1989) Early morning hyperglycaemia in IDD: acute and sustained effects of cholinergic blockade. J Clin Endocrinol Metab (in press)Google Scholar
  3. Baird A, Mormede P, Ying SY (1985) A nonmitogenic pituitary function of fibroblast growth factor: regulation of thyrotrophin and prolactin secretion. Proc Natl Acad Sci USA 82 (16): 5545–5549PubMedCrossRefGoogle Scholar
  4. Bear JC, Briones-Urbina R, Fahey JF, Farid NR (1985) Variant multiple endocrine neoplasia I (MEN IBorin): Further studies on non-linkage to HLAP1. Hum Hered 35: 15–20PubMedCrossRefGoogle Scholar
  5. Bertrand G, Tolis G, Montes J (1983) Immediate and long-term results of transsphenoidal microsurgical resection of prolactinomas in 92 patients. In: Tolis G, Stefanis C, Mountokalakis T, Labrie F (eds) Prolactin and prolactinomas Raven Press, New York, pp 441Google Scholar
  6. Bevan JS, Adams CBT, Burke CW, Morton KE, Molyneux M, Moore RA, Esiri MM (1987) Factors in the outcome of trans-sphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy. Clin Endocrinol 26: 541–556CrossRefGoogle Scholar
  7. Billestrup N, Mitchell RM, Vale W, Verma JM (1987) Growth hormone releasing factor induces c-fos expression in cultured primary pituitary cells. Mol Endocrinol 1 (4): 300–305PubMedCrossRefGoogle Scholar
  8. Billestrup N, Swanson LW, Vale W (1986) Growth hormone releasing factor stimulates proliferation of somatotrophs in vitro. Proc Natl Acad Sci USA 83 (18): 6854–6857PubMedCrossRefGoogle Scholar
  9. Buchfelder M, Lierheimer A, Schrell U (1985) Recurrence of hyperprolactinaemia detected in long-term follow-up of surgically normalized microprolactinomas. In: Auer LM, Leb G, Tscherne G, Urdle W, Walter GF (eds) Prolactinomas. Walter de Gruyter, Berlin New York, pp 183–187Google Scholar
  10. Cann CE, Martin MC, Harry K, Genant HK, Jaffe RB (1984) Decreased spinal mineral content in amenorrheic women. JAMA 251: 626–629PubMedCrossRefGoogle Scholar
  11. Chrousos GP, Schürmeyer TH, Doppman J, Oldfield EH, Schulte HM, Gold PW, Loriaux DL (1985) Clinical applications of corticotropin releasing factor. Ann Intern Med 102: 344–358PubMedGoogle Scholar
  12. Ciccarelli E, Savino L, Carlevatto V, Bertagna A, Isaia GC, Camanni F (1988) Vertebral bone density in non-amenorrhoeic hyperprolactinaemic women. Clin Endocrinol 28: 1–6CrossRefGoogle Scholar
  13. Dieguez C, Page MD, Scanlon MF (1988) Growth hormone neuroregulation and its alterations in disease states. Clin Endocrinol 28: 109–143Google Scholar
  14. Fahlbusch R, Buchfelder M, Werder K (1984) Present status of surgical treatment of prolactinomas (and long term follow-up). In: Lamberts SW, Tilders FJH, Van der Veen EA, Assies J (eds) Trends in diagnosis and treatment of pituitary adenomas. Free University Press, Amsterdam, pp 121–132Google Scholar
  15. Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Paracchi A, Romano C, Boghen M, Dubini A (1986) Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinaemic patients. J Clin Endocrinol Metab 63: 941–945PubMedCrossRefGoogle Scholar
  16. Gillies GE, Lowry PJ (1986) Adrenal function. In: Lightman SL, Everitt BJ. (eds) Neuroendocrinology. Blackwell Scientific Publications, Oxford, pp 360–388Google Scholar
  17. Ikeda H, Mitsuhashi T, Kubota K, Kuzuya N, Uchimura H (1984) Epidermal growth factor stimulates growth hormone secretion from superfused rat adenohypophyseal fragments. Endocrinology 115: 556–558PubMedCrossRefGoogle Scholar
  18. Page et al.: A Clinical Update on Hypothalamic-Pituitary ControlGoogle Scholar
  19. Isaacs RE, Findell PR, Gertz BJ, Baxter JD (1987) C-myc gene expression in human growth hormone-secreting pituitary adenomas: regulation by glucocorticoids. Clin Res 35: 396AGoogle Scholar
  20. Johnson LK, Baxter JD, Vlodausky I, Gospodarowicz D (1980) Epidermal growth factor and expression of specific genes: effects on cultured rat pituitary cells are dissociable from the mitogenic response. Proc Natl Acad Sci USA 77 (1) 394–398PubMedCrossRefGoogle Scholar
  21. Jordan V, Dieguez C, Valcavi R, Artioli C, Portioli I, RodriguezArnao MD, Gomez-Pan A, Hall R, Scanlon F (1986) Lack of effect of muscarinic cholinergic blockade on the GH responses to GRF 1–29 and TRH in acromegalic subjects. Clin Endocrinol 24: 415–420CrossRefGoogle Scholar
  22. Klibanski A, Greenspan SL (1986) Increase in bone mass after treatment of hyperprolactinaemic amenorrhoea. N Eng J Med 315: 542–546CrossRefGoogle Scholar
  23. Klibanski A, Robert MD, Neer M, Beitins IZ, Chester Ridgway E, Zervas NT, McArthur JW (1980) Decreased bone density in hyperprolactinaemic women. N Engl J Med 303: 1511–1513PubMedCrossRefGoogle Scholar
  24. Knobil E (1980) The neuroendocrine control of the menstrual cycle. Recent Prog Hor Res 36: 53–58Google Scholar
  25. Koppelman MCS, Kurtz DW, Morrish KA, Bou E, Susser JK, Shapiro JR, Loriaux DL (1984) Vertebral body bone mineral content in hyperprolactinaemic women. J Clin Endocrinol Metab 59: 1050–1053PubMedCrossRefGoogle Scholar
  26. Kudlow JE, Kobrin MS (1984) Secretion of epidermal growth factor-like mitogens by cultured cells from bovine anterior pituitary glands. Endocrinology 115: 911–917PubMedCrossRefGoogle Scholar
  27. Landolt AM, Valavanis A, Girard J, Eberle AN (1986) Corticotropin-releasing factor test used with bilateral, simultaneous inferior petrosal sinus blood-sampling for the diagnosis of pituitary-dependent Cushing’s disease. Clin Endocrinol 25: 687–696CrossRefGoogle Scholar
  28. Mason P, Adams J, Morris D, Tucker M, Price J, Voulgaris Z, Van der Spuy ZM, Sutherland I, Chambers GR, White S et al (1984) Induction of ovulation with pulsatile luteinising hormone-releasing hormone. Br Med J 288: 181–185CrossRefGoogle Scholar
  29. Massara F, Ghigo E, Molinatti P, Mazza E, Locatelli V, Muller EE, Camanni F (1986) Potentiation of cholinergie tone by pyridostigmine bromide reinstates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone releasing factor in man. Acta Endocrinol (Copenh) 113: 12–16Google Scholar
  30. Melmed S (1988) Pituitary growth factors. In: Scanlon MF, Wass JAH (eds) Neuroendocrine perspectives. Springer, New York (in press)Google Scholar
  31. Michard M, Birman P, Peillon F, Bression D (1986) EGF receptors present in normal rat and human pituitaries are absent in human PRL, GH, and non-secreting pituitary adenomas. First Inter Con Neuroendocrin, San Francisco, Abstract 146Google Scholar
  32. Muller OA, von Werder K (1988) Diagnostic dilemmas in hypercortisolism: investigation and management. In: Scanlon MF, Wass JAH (eds) Neuroendocrine perspectives. Springer, New York (in press)Google Scholar
  33. Murdoch GH, Potter E, Nicolaisen AK, Evans RM, Rosenfeld MG (1982) Epidermal growth factor rapidly stimulates prolactin gene transcription. Nature 300: 192–194PubMedCrossRefGoogle Scholar
  34. Page MD, Koppeschaar HPF, Dieguez C, Gibbs JT, Hall R, Peters JF, Scanlon MF (1987) Cholinergic muscarinic receptor blockade with pirenzepine abolishes slow wave sleep-related GH release in young patients with insulin dependent diabetes mellitus. Clin Endocrinol 26: 355–359CrossRefGoogle Scholar
  35. Page MD, Millward ME, Hourihan M, Hall R, Scanlon MF (1989) Long term treatment of acromegaly with a long-acting analogue of somatostatin, Ocreotide. Q J Med (submitted)Google Scholar
  36. Peters JR, Evans PJ, Page MD, Hall R, Gibbs JT, Dieguez C, Scanlon MF (1986) Cholinergie muscarinic receptor blockade with pi-renzepine abolishes slow wave sleep-related growth hormone release in normal adult males. Clin Endocrinol 25: 213–217CrossRefGoogle Scholar
  37. Robinson ICAF (1986) The magnocellular and parvocellular OT and AVP systems. In: Lightman SL, Everitt BJ (eds) Neuroendocrinology. Blackwell Scientific Publications, Oxford, pp 154–176Google Scholar
  38. Sawchenko PE, Swanson LW, Vale WW (1984) Co-expression of corticotropin-releasing factor and vasopressin immunoreactivity in parvocellular neurosecretory neurons of the adrenalectomised rat. Proc Natl Acad Sci USA 81: 1883–1887PubMedCrossRefGoogle Scholar
  39. Scanlon MF, Peters JR, Thomas JP, Richards SH, Morton WH, Howell S, Williams ED, Hourihan M, Hall R (1985) Management of selected patients with hyperprolactinaemia by partial hypophysectomy. Br Med J 291: 1547–1550CrossRefGoogle Scholar
  40. Rodriguez-Arnao MD, McGregor AM, Weightman D, Lewis M, Cook DB, Gomez-Pan A, Hall R (1981) Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function. Clin Endocrinol 14: 133–143CrossRefGoogle Scholar
  41. Schlechte JA, Sherman BM, Chapler FK, Van Gilder J (1986) Long term follow-up of women with surgically treated prolactin-secreting pituitary tumours. J Clin Endocrinol Metab 62: 1296–1301PubMedCrossRefGoogle Scholar
  42. Schlechte JA, Sherman BM, Martin R (1983) Bone density in amenorrhoeic women with and without hyperprolactinaemia. J Clin Endocrinol Metab 56: 1120–1123PubMedCrossRefGoogle Scholar
  43. Schonbrunn A, Krasnoff H, Westendorf JM, Tashjian AH (1980) Epidermal growth factors and thyrotrophin-releasing hormone act similarly on a clonal pituitary cell strain. Modulation of hormone production and inhibition of cell proliferation. J Cell Biol 85 (3): 786–797PubMedCrossRefGoogle Scholar
  44. Schulte HM, Allolio B, Günther RW, Benker G, Winkelmann W, Ohnhaus EE, Reinwein D (1988) Selective bilateral and simultaneous catheterization of the inferior petrosal sinus: CRF stimulates prolactin secretion from ACTH-producing microadenomas in Cushing’s disease. Clin Endocrinol 28: 289–295Google Scholar
  45. Serri O, Rasio E, Beauregard H, Hardy J, Somma M (1983) Recurrence of hyperprolactinaemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 309: 280–283PubMedCrossRefGoogle Scholar
  46. Sherry SH, Guay AT, Lee AK, Hedley-White ET, Federmann M, Freidberg SR, Woolf PD (1982) Concurrent production of adrenocorticotropin and prolactin from two distinct cell lines in a single pituitary adenoma: a detailed immunohistochemical analysis. J Clin Endocrinol Metab 55: 947–955PubMedCrossRefGoogle Scholar
  47. Sullivan NJ, Tashjian AH (1983) Platelet-derived growth factor selectively decreases prolactin production in pituitary cells in culture. Endocrinology 113: 639–645PubMedCrossRefGoogle Scholar
  48. Teasdale G (1983) Surgical management of pituitary adenoma. In: Scanlon MF (ed) Clinics in endocrinology and metabolism. WB Saunders Co Ltd, London, pp 789–823Google Scholar
  49. Thomson JA, Teasdale GM, Gordon D, McCruden DC, Davies DL (1985) Treatment of presumed prolactinomas by transsphenoidal operation: early and late results. Br Med J 291: 1550–1553CrossRefGoogle Scholar
  50. Vale W, Spiess J, Rivier C, Rivier J (1981) Characterisation of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and B-endorphin. Science 213: 1394–1397PubMedCrossRefGoogle Scholar
  51. Weeks I, Sturgess M, Siddle S, Jones MK, Woodhead JS (1984) A high sensitivity immunochemiluminometric assay for human thyrotrophin. Clin Endocrinol 20: 489–495CrossRefGoogle Scholar
  52. Weiner RI, Elias KA, Monnet F (1985) The role of vascular changes in the aetiology of prolactin secreting anterior pituitary tumours. In: MacLeod RM, Thorner MO, Scapagnini U (eds) Prolactin basic and clinical correlates. Springer, New York, pp 641–653Google Scholar
  53. White JD, Carlson HE (1987) Increased oncogene expression in rat pituitary tumours. In: Habener JF, Means AR, Ringold GM, Rosenfeld MG (eds) Programme and Abstracts: The Endocrine Society 69th Annual Meeting Indiana. Bethesda, Endocrine Society, Abst 650, pp 183Google Scholar
  54. Winkelmann W, Allolio B, Deuss U, Heesen D, Kaulen D (1985) Persisting normoprolactinaemia after withdrawal of bromocriptine long-term therapy in patients with prolactinomas. In: MacLeod RM, Thorner MO, Scapagnini U (eds). Prolactin: basic and clinical correlates. Liviana Press, Padova, pp 817–822Google Scholar
  55. Wolfson B, Manning RW, Davis LG, Arentzen R, Baldina F (1985) Co-localisation of corticotrophin-releasing factor and vasopressin mRNA in neurons after adrenalectomy. Nature 315: 59–61PubMedCrossRefGoogle Scholar
  56. Yamaji T,Ishibaski M, Teramoto A, Fukushima T (1984) Hyperprolactinaemia in Cushing’s disease and Nelson’s syndrome. J Clin Endocrinol Metab 58: 790–795PubMedCrossRefGoogle Scholar
  57. Yamaji T,Ishibaski M, Teramoto A, Fukushima T(1985) Prolactin secretion by mixed ACTH-prolactin pituitary adenoma cells in culture. Acta Endocrinol (Copenh) 108:456–463PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • M. D. Page
    • 1
  • J. Webster
    • 1
  • C. Dieguez
    • 1
  • R. Hall
    • 1
  • M. F. Scanlon
    • 1
  1. 1.Neuroendocrine Unit, Department of MedicineUniversity of Wales College of MedicineCardiffWales

Personalised recommendations